A randomized, double-masked, placebo-controlled two cross-over study comparing the effects of moxaverine and placebo on ocular blood flow

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001783-23-AT

Enrollment

Registered

2006-07-21

Start date

2006-07-26

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy persons

Interventions

Product Name: Moxaverin in Ringer Lactat Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Moxaverine Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: healthy persons Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Symptoms of any systemic disease, abuse of medications, beverages or drugs

Design outcomes

Primary

Measure	Time frame
Main Objective: Effect of moxaverine in comparison to placebo on ocular blood flow;Secondary Objective: no;Primary end point(s): Retinal, choroidal and optic nerve head blood flow	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026